bupropion (Wellbutrin SR)

How long the trials actually ran

The longest trial behind the bupropion approval ran 6 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

How many Americans take bupropion

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

34,895,515

prescriptions in the United States (2024)

8,042,017

people filling them (2024)

Prescriptions are up 39% since 2014. Whatever you decide about bupropion, you are deciding alongside about 8,042,017 other people this year.

Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.

What people report to the FDA about bupropion

152,137

reports mentioning bupropion, all time

83,540

filed as serious (a report-level flag covering every drug and outcome in the report)

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.

Known interactions, from the label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

FDA label for bupropion, effective August 27, 2026 — DailyMed.

Who pays for bupropion

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 2,224,023 beneficiaries filled 9,811,789 claims in 2024 — 1,692,577 aged 65 and over, and 531,446 under 65.

Medicaid

At least 6,860,093 prescriptions in 2024 — a floor, because 333 of 1,765 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

The MEPS-based estimate above puts the whole country at 34,895,515 prescriptions and 8,042,017 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of bupropion specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

The approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   The efficacy of the immediate-release formulation of bupropion in the treatment of major depressive disorder was established in two 4-week, placebo-controlled trials in adult inpatients with MDD (Trials 1 and 2 in Table 6) and in one 6-week, placebo-controlled trial in adult outpatients with MDD (Trial 3 in Table 6).

   FDA-approved labelling, 14 CLINICAL STUDIES — read the label on DailyMed

   Our reading

   Three trials, and every one of them in a formulation almost nobody is prescribed now. Sustained- and extended-release bupropion were bridged to these results on pharmacokinetic grounds rather than re-proven on their own efficacy evidence. The trials were also very small — Trial 1 randomised 48 people to bupropion and 27 to placebo — and Trial 2 only separated from placebo at 450 mg/day, above the dose most people take.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   October 4, 1996

   Application

   NDA020358

   Review

   STANDARD

   Original sponsor

   GlaxoSmithKline

   Holds it now

   GlaxoSmithKline

   Label submissions since

   60

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • The antidepressant suicidality warning has an age ceiling most people never hear about

     Antidepressants carry a boxed warning about suicidal thoughts and behaviour in children, adolescents and young adults. It came from pooling 24 short-term placebo-controlled trials of nine antidepressants in more than 4,400 young patients: suicidality was reported in about 4% on drug against 2% on placebo. There were no completed suicides in those trials.

     The part that usually gets lost is the age boundary, which is in the label itself. The studies did not show an increased risk above age 24, and in patients 65 and older the risk went in the other direction — it was reduced. The warning is real and it is specific, not a blanket statement about everyone who takes one.

     Worth asking

     Given my age, which side of that line am I on, what specifically should I or the people around me watch for in the first two months, and who do I call if it happens.

     PROZAC (fluoxetine) prescribing information — Boxed Warning: Suicidal Thoughts and Behaviors — U.S. Food and Drug Administration (approved labelling)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major…

     22 years after approval

     In a network meta-analysis of 522 randomized trials (116,477 adults with major depression), bupropion, like all 21 antidepressants studied, was more effective than placebo (odds ratios across drugs ranged from 1.37 to 2.13), although the certainty of evidence for most bupropion comparisons was rated low to very low.

     Worth asking

     Worth asking your prescriber how bupropion compares with other first-line antidepressants for your particular symptom pattern, since head-to-head evidence for bupropion is thinner than for some alternatives.

     Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis — Cipriani A, et al. (2018)

   • Antidepressants for smoking cessation

     27 years after approval

     High-certainty evidence from 50 randomized trials (18,577 people) shows bupropion increases six-month-or-longer quit rates by about 60% versus placebo (risk ratio 1.60, 95% CI 1.49 to 1.72), with more dropouts due to side effects (RR 1.44) and no clear increase in serious adverse events (RR 1.16, CI includes 1).

     Worth asking

     Worth asking your prescriber whether bupropion, nicotine replacement, or varenicline is the best fit for you if quitting smoking is a goal, since bupropion works but was less effective than varenicline in this review.

     Antidepressants for smoking cessation — Hajizadeh A, et al. (2023)

   • Withdrawal from these medications can take months, and NICE says so

     26 years after approval

     NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.

     It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.

     That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.

     Worth asking

     Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.

     Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215) — National Institute for Health and Care Excellence (2022)

   • Strategies for managing sexual dysfunction induced by antidepressant medication.

     17 years after approval

     Across 23 randomised trials and 1,886 people, adding sildenafil (3 trials, 255 men) or tadalafil (1 trial, 54 men) improved erectile function in men more than placebo; for women the reviewers concluded it remains uncertain whether sildenafil beats placebo. Bupropion 150 mg twice daily beat placebo on rating-scale scores (SMD 1.60, 95% CI 1.40 to 1.81) across three trials, but 150 mg once daily did not (RR 0.62, 95% CI 0.09 to 4.41). Every other augmentation strategy failed, only one trial studied switching antidepressant, and no trial tested psychological approaches or drug holidays.

     Worth asking

     If I want to stay on this antidepressant, is adding sildenafil or twice-daily bupropion an option for me, or would switching drugs be the better first move?

     Strategies for managing sexual dysfunction induced by antidepressant medication. — Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. (2013)

   • In 2019 the Royal College of Psychiatrists changed its position on withdrawal

     23 years after approval

     For years people reporting long, severe antidepressant withdrawal were told it lasted a week or two. In May 2019 the Royal College of Psychiatrists published a position statement conceding the point: while withdrawal symptoms are often mild and self-limiting, there is substantial variation, and for some patients symptoms last much longer and are more severe.

     It went further and asked for changes — that guidelines and patient information recognise the potential for severe and long-lasting withdrawal, that pharmacologically-informed tapering guidance be developed, that discontinuation be tapered at a rate the patient can tolerate over potentially several months, and that clinicians actively work to tell withdrawal apart from relapse.

     One thing it explicitly does not say, and it is worth being accurate about: the College states that from a clinical perspective antidepressant use is not associated with dependence in the addiction sense. Withdrawal and dependence are not the same claim.

     Worth asking

     If I feel bad three weeks after a dose reduction, how will we decide whether that is withdrawal or my depression returning, and what do we do differently in each case.

     Position statement on antidepressants and depression (PS04/19) — Royal College of Psychiatrists (2019)

   • Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder…

     21 years after approval

     In 1,522 veterans whose depression had not responded to an antidepressant, switching to bupropion led to remission in 22.3% versus 26.9% for adding bupropion and 28.9% for adding aripiprazole; only aripiprazole augmentation significantly beat the bupropion switch (RR 1.30, 95% CI 1.05 to 1.60).

     Worth asking

     Worth asking your prescriber whether adding bupropion to your current antidepressant, rather than switching outright, is an option if your current medication has not fully worked.

     Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial — Mohamed S, et al. (2017)

   • Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a…

     9 years after approval

     In pooled patient-level data from 7 randomized trials (732 bupropion, 731 SSRI, 512 placebo patients), bupropion matched SSRIs on remission (47% vs 47%, both above placebo's 36%) while causing no more sexual dysfunction than placebo, whereas SSRIs caused significantly more sexual side effects than either.

     Worth asking

     Worth asking your prescriber about bupropion if sexual side effects on an SSRI are a problem for you, since trial data show similar depression outcomes with fewer sexual side effects.

     Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials — Thase ME, et al. (2005)

   • Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.

     13 years after approval

     When sexual function is actually asked about with a questionnaire rather than waited for as a spontaneous complaint, treatment-emergent sexual dysfunction ranged from 25.8% to 80.3% of patients across antidepressants, all significantly above placebo. In descending order of impact the drugs were sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, and fluvoxamine. Agomelatine, amineptine, bupropion, moclobemide, mirtazapine, and nefazodone showed no significant difference from placebo.

     Worth asking

     Where does the antidepressant I'm on sit on the sexual side-effect ranking, and is there a drug with a lower rate that would still treat my condition?

     Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. — Serretti A, Chiesa A. (2009)

   • The biggest trial of quit-smoking drugs in people with mental illness was paid for by the makers

     20 years after approval

     EAGLES randomised 8,144 smokers, roughly half of them with a psychiatric diagnosis, against nicotine patch and placebo. Neither varenicline nor bupropion produced an excess of moderate or severe neuropsychiatric events - serious mood, thinking or behaviour problems.

     Having a psychiatric condition raised the event rate. The medication did not. The FDA dropped its boxed warning largely on this result.

     Significant findings

     Industry-funded trials reach sponsor-friendly conclusions about 1.4 times as often as independently funded ones (Lundh, Cochrane 2017).

     That gap survives adjusting for how well each trial was run. Nobody falsified anything. It is the thousand small choices in designing and writing up a trial, leaning on average toward whoever paid.

     Pfizer and GlaxoSmithKline employees are named authors here.

     Worth asking

     The design is genuinely excellent, and the evidence is still a company's evidence about its own drug. Both halves belong on the label. If you want to quit and you take psychiatric medication, ask your prescriber what the real risk is now. Never start or stop a medication on your own.

     Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial — Anthenelli RM, et al. (2016)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • The efficacy evidence is for immediate-release in inpatients over four to six weeks. Most prescriptions today are XL, outpatient, and long-term.
   • Trial 2 demonstrated effectiveness only at 450 mg/day. What does that imply about the dose you are on?
   • What is the long-term evidence for the formulation you are actually taking?
   • Seizure risk was the historical concern that shaped the dosing. Does your dose and history account for it?